Tests a radioactive antibody before stem cell transplant in high-risk leukemia
Tests a radioactive antibody before donor stem cell transplant in adults with leukemia.
Key facts
- Who runs it
- Fred Hutchinson Cancer Center
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 30 people, planned
- Started
- 10 Jul 2019
- Expected to end
- 20 Oct 2029
- Type of study
- Interventional
- Treatments tested
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- Cyclophosphamide
- Total-Body Irradiation
- Peripheral Blood Stem Cell Transplantation
- Bone Marrow Transplantation
- Mycophenolate Mofetil
- Recombinant Granulocyte Colony-Stimulating Factor
- Fludarabine Phosphate
- Tacrolimus
- Bone Marrow Aspiration and Biopsy
- Biospecimen Collection
- Record updated
- 22 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with high-risk acute leukemia or high-risk myelodysplastic syndrome. They need a related donor for a stem cell transplant.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid, acute lymphoblastic or mixed phenotype leukemia in first remission with measurable residual disease, relapsed, or refractory; AML that evolved from myelodysplastic or myeloproliferative syndromes; MDS with excess blasts; or chronic myelomonocytic leukemia. Those not in remission need leukemic cells that carry CD45.
- Earlier treatment
- People who had a reduced-intensity or non-myeloablative donor transplant before can join if they have no ongoing graft versus host disease and have been off all immunosuppression for at least 6 weeks. People who had a prior myeloablative donor transplant cannot join.
- Biomarker or test result
- Not in remission: leukemic blasts that express CD45. Circulating blast count under 10,000/mm^3. A related donor who shares one HLA haplotype.
Main reasons for not taking part
- Active leukemia in the central nervous system
- Known HIV infection
- Serious heart, lung or liver problems, such as left ventricular ejection fraction under 45%
- Pregnant or breast feeding
- Allergy to murine-based monoclonal antibodies
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Patients must have AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions:; AML, ALL, or MPAL in first remission with evidence of measurable residual disease (MRD) by flow cytometry; AML, ALL, or MPAL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen); AML, ALL, or MPAL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens); AML evolved from myelodysplastic or myeloproliferative syndromes; MDS expressed as refractory anemia with excess blasts (RAEB); Chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria
- Patients not in remission must have CD45-expressing leukemic blasts. Patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative (because in remission patients, virtually all antibody binding is to non-malignant cells which make up >= 95% of nucleated cells in the marrow)
- Patients must be >= 18 and =< 75 years of age
- Patients should have a circulating blast count of less than 10,000/mm\^3 (control with hydroxyurea or similar agent is allowed)
- Patients must have an estimated creatinine clearance greater than 50/ml per minute by the following formula (Cockcroft-Gault). Serum creatinine value must be within 28 days prior to registration
- Total bilirubin within normal limits
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
- Eastern Cooperative Oncology Group (ECOG) < 2 or Karnofsky >= 70
- Patients must be free of uncontrolled infection
- Patients with prior non-myeloablative or reduced-intensity conditioning allogeneic-HCT must have no evidence of ongoing GVHD and be off all immunosuppression for at least 6 weeks at time of enrollment
- Patients must have normal elastography
- If ferritin is elevated, patient must have less than 7 mg/g liver iron concentration on liver T2 magnetic resonance imaging (MRI)
- Patients should have an official gastrointestinal (GI) consult prior to the transplant for full evaluation
- Patients must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches
- DONOR: Donors must meet HLA matching criteria as well as standard Seattle Cancer Care Alliance (SCCA) criteria for PBSC or bone marrow donation. Preference should be given to donors who are mismatched at the HLA-A, -B and -DRB1 loci
Who cannot take part
- Corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygen. When pulmonary function tests (PFTs) cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of < 89% during a 6MWT will be excluded
- Patients with prior myeloablative allogeneic-HCT
- Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
- Known contraindications to radiotherapy
- Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects
- Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease
- Patients who are known to be seropositive for human immunodeficiency virus (HIV)
- Allergy to murine-based monoclonal antibodies
- Left ventricular ejection fraction < 45%
- Perceived inability to tolerate diagnostic or therapeutic procedures
- Active central nervous system (CNS) leukemia at time of treatment
- Women of childbearing potential who are pregnant (beta human chorionic gonadotropin [B-HCG]+) or breast feeding
- Inability to understand or give an informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Phuong VoTaking people
About the trial
What the trial wants to find out
This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). 211At-BC8-B10 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy and total body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can attack the body's normal cells, called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, and tacrolimus after a transplant may stop this from happening.
The group in the trial
- Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)Treatment being tested
PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8, fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on days -6 and -5. Patients also undergo TBI on day -1. TRANSPLANT: Patients undergo PBSC or bone marrow transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID on days 5-35, and tacrolimus IV over 1-2 hours (changed to PO once tolerated) on days 5-180 with taper beginning on day 84 per physician discretion. Patients also begin G-CSF IV or SC on day 5 to continue until ANC \> 1000/mm\^3 x 3 days. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
Treatment: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, and Biospecimen Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Plain-language title
- Tests a radioactive antibody before stem cell transplant in high-risk leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03670966, who can take part
- Record updated
- 22 June 2026